|
One year follow up of kidney-transplanted patients who received Rabbit anti-thymocyteglobulinis
|
|
| Author:
|
LEILA MALEKMAKAN, TARANEHTADAYON, ZYNAB KARIMI, ALI ALRASHID
|
| Abstract:
|
Rabbit anti-thymocyteglobulinis (rATG) the most common drug, used for induction therapy in renal transplanted
patient. Though, it still has not been approved by FDA. This studyaimed to evaluate the outcome of kidney
transplanted patients who received rATG for induction. We gathered data of 54 patients who went under kidney
transplantation and received rATG as induction therapy from 2013 till 2016. Also we followed these patients for one
year and recorded their outcome. The mean age of patients was 40.2±11.6 and 32 patients (59.3%) were male.
Generally, 66.7% (36 patients) of our patients experienced survived graft, 11.1% (6 patients) lost their graft, 3.7% (2
patients) experienced acute rejection and 20.4% (10 patients) of patients died during the study. Dead was occurred
more in patients who suffered from both hypertension and diabetes and patients with cardiovascular disease
(p=0.045, 0.023). Also graft loss was seen more in patients with re-transplant (p=0.012). Over all 3.8% (2 patients) of
our patients developed malignancy. A wide variety of ranges reported for survival, graft loss, acute rejection and
deathof patients who received rATG which is mostly due to small number of population. As a result, study with larger
population must be done. Also malignancy is a lethal side effect of this drug that more studies must be done to
determine the vulnerable patients.
|
| Keyword:
|
ESRD; rATG; Transplant
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2019.11.01.048
|
| Download:
|
Request For Article
|
|
|